- Lonza and Bristol Myers Squibb have entered into an exclusive single-target licensing agreement focused on an antibody-drug conjugate (ADC) program.
- Bristol Myers Squibb will gain exclusive access to Lonza’s SYNtecan™ linker-payload platform for an ADC targeting an undisclosed indication.
Lonza and Bristol Myers Squibb have announced an exclusive single-target licensing agreement centered on Lonza’s SYNtecan™ linker-payload platform for antibody-drug conjugate (ADC) development.
Under the agreement, Bristol Myers Squibb will receive exclusive access to the platform to advance an ADC against an undisclosed target. The pharmaceutical company will be responsible for the research, development, manufacturing, and commercialization of the resulting ADC program.
Lonza stated that, through one of its affiliated companies, it will be eligible to receive upfront payments, milestone payments, and royalties on net sales of products developed under the agreement. Financial terms were not disclosed.
The SYNtecan™ platform is based on TOPO1 inhibitor linker-payload technology used in ADC development. The agreement further expands Lonza’s role in supporting biopharmaceutical development and contract manufacturing activities related to complex oncology modalities.
“Licensing SYNtecan™ linker-payloads, our TOPO1 inhibitor platform, to BMS provides another strong validation of its strength and its trustworthiness in delivering positive clinical outcomes.”
Jan Vertommen, Vice President of Commercial Development, Advanced Synthesis at Lonza
